Bristol Myers Squibb

Bristol Myers Squibb (Ticker: NYSE: BMY) is a medicines and science company dating back over 135 years. Starting out by Edward Robinson Squibb who was born on the 4th July 1819 in Wilmington, Delaware, USA.

Edwards aim was to provide high quality standardised medicines after spending 10 years in the navy as a surgeon. A crusader against impure drugs and at request from the government in 1847 he set up a laboratory in a Naval Hospital in Brooklyn New York. In 1852 he starts production of Ether by distillation in a way to provide relief to suffering patients going through operations with no anaesthesia. From here the company structure starts being joined along the way by fellow scientists William McLaren Bristol (1887) & right up to 1989 when Bristol Myers & Squibb companies merge. The full and extremely interesting history is can be found on their website by clicking here.

Today Bristol Myers Squibb is a global biopharmaceutical company that focuses in the unmet needs of patients with serious diseases.

The company has an array of products / medicines that are available which is far too many to list, however these is a link provided to their website here.

This is what I would deem to be a quality medicines business in that today its focuses in the following specialist fields like: Oncology, Hematology, Immunology, Cardiovascular & Fibrosis.

Here are 10 reasons behind my thesis for an investment case:

1, Global sales annually of $45.06 Billion (31/12/24)

2, Extensive pipeline of drugs in development trials

3, BMY has been a dividend paying company for over 50 years (Historical dividends can be found here)

4, Areas of interest Gene Therapy

5, Areas of interest Protein Homeostasis

6, Areas of interest Cell Therapy

7, Areas of interest Drug Delivery technology

8, Areas of interest Antibody Drug Conjugates

9, BMY have been on an acquisition trail in recent years picking up company’s like Celgene in 2019 & MyoKardia in 2020

10, BMY have a history of partnerships and collaborations with various companies in developing the next generations of medicines that builds on their heritage in developing blockbuster drugs.

Bristol Myers Squibb current fundamentals are:

P/E: 14.06% (31/03/2024)

Fwd P/E: 7.97% (31/03/2024)

EPS: 3.86 (31/03/2024)

Dividend yield is 4.43% (31/03/24)

Quarterly dividends have increased recently from $0.57 to $0.60 cents or $2.40 dollars annualised (Ex Div : 04/04/2024)

BMY have been raising payouts for the last 16 years

This equity has been held in the portfolio for 3.5 years (14 quarters) total quantity 65 shares.

During the last quarter of 2023 I increased the holdings by 25 shares taking the total to 90 shares, with the intention to 

Please see the below file providing a full break down of the earnings received totalling £398.26